%0 Journal Article
%T Efficacy of the anti-VZV (anti-HSV3) vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study
%A Le Goaster J
%A Gonzalo S
%A Bouree P
%A Tangy F
%A Haenni AL
%J Open Access Journal of Clinical Trials
%D 2012
%I Dove Medical Press
%R http://dx.doi.org/10.2147/OAJCT.S33292
%X acy of the anti-VZV (anti-HSV3) vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study Case report (11544) Total Article Views Authors: Le Goaster J, Gonzalo S, Bouree P, Tangy F, Haenni AL Published Date July 2012 Volume 2012:4 Pages 51 - 58 DOI: http://dx.doi.org/10.2147/OAJCT.S33292 Received: 25 April 2012 Accepted: 01 June 2012 Published: 30 July 2012 Jacqueline Le Goaster,1 Sylvie Gonzalo,2 Patrice Bour¨¦e,1 Frederic Tangy,3 Anne-Lise Haenni4 1Department of Tropical Diseases, Centre Hospitalo-Universitaire (CHU), University of Paris XI, Le Kremlin Bic¨ºtre, 2Biomnis Laboratory, Ivry-sur-Seine, 3Retro-Virology, Centre National de Recherche Scientifique (CNRS), Pasteur Institute, Paris; 4Jacques Monod Institute, Centre National de Recherche Scientifique (CNRS), University of Paris VII, Paris, France Background: The aim of this study was to evaluate the possibility of using the anti-varicella zoster virus (anti-VZV, also known as anti-HSV3) vaccine against orobuccal herpes simplex virus type 1 (HSV1) and genital herpes simplex virus type 2 (HSV2). This was suggested by study of the phylogenetic tree of members of the herpes virus family, which showed a close relationship between VZV (HSV3) and the HSV1 and HSV2 herpes viruses. Methods: The present prospective study was conducted from January 2005 through January 2011. Twenty-four patients afflicted with HSV1 and HSV2 herpes recurrences over a period of years, numbering 6¨C8 and more recurrences per year, agreed to receive the anti-VZV vaccine. They were compared with 26 nonvaccinated patients presenting with herpes simplex diseases 2¨C5 times a year. All 50 patients were documented with anti-HSV1, anti-HSV2, and anti-VZV antibody serological testing. Results: From 2005 through 2011, for the 24 anti-VZV vaccinated patients, the average number of herpes relapses decreased to 0, correlated with an increased anti-VZV antibody level and clinical recovery of all patients, whereas no improvement was observed for the 26 nonvaccinated herpes patients. Conclusion: Data for the anti-VZV serological antibody levels tested before and after anti-VZV vaccination showed a significant (P < 0.001) increase among vaccinated patients. This suggests defective anti-VZV immune power in these patients. After 6 years of positive results for anti-VZV vaccine, this is a logical and fair hypothesis. We can now undertake a randomized study to confirm these findings.
%K HSV1/HSV2 herpes prevention
%K anti-VZV (HSV3) vaccine
%K anti-VZV vaccine therapy
%U https://www.dovepress.com/efficacy-of-the-anti-vzv-anti-hsv3-vaccine-in-hsv1-and-hsv2-recurrent--peer-reviewed-article-OAJCT